Literature DB >> 16254190

Induction of invasive mouse skin carcinomas in transgenic mice with mutations in both H-ras and p53.

Zhongqiu Zhang1, Ruisheng Yao, Jie Li, Yian Wang, Charles W Boone, Ronald A Lubet, Ming You.   

Abstract

Synergistic interaction between H-ras and p53 were systematically examined during skin tumorigenesis. Concurrent expression of an activated H-ras gene and a mutant p53 gene was accomplished by crossing p53(Val135/wt) mice with TG.AC mice. Topical application to wild-type mice with benzo(a)pyrene (BaP) alone produced approximately 26% skin tumor incidence, whereas BaP treatment of p53(wt/wt)Hras(TG.AC/wt), p53(Val135/wt)Hras(wt/wt), and p53(Val135/wt)Hras(TG.AC/wt) mice produced a 75%, 77%, and 100% incidence of skin tumors, respectively. An average of 0.33 tumor per mouse was observed in wild-type (p53(wt/wt)Hras(wt/wt)) mice, whereas approximately 1.54, 1.96, and 3.08 tumors per mouse were seen in BaP-treated p53(wt/wt)Hras(TG.AC/wt), p53(Val135/wt)Hras(wt/wt), and p53(Val135/wt)Hras(TG.AC/wt) mice, respectively. The effects on total tumor volume were even more striking with 7-, 48-, and 588-fold increases in tumor volume compared with wild-type (p53(wt/wt)Hras(wt/wt)) in p53(wt/wt)Hras(TG.AC/wt), p53(Val135/wt)Hras(wt/wt), and p53(Val135/wt)Hras(TG.AC/wt) mice, respectively. Histopathologically, all tumors from p53(wt/wt)Hras(wt/wt) mice were either papillomas or well-differentiated squamous cell carcinomas, whereas the tumors in p53(wt/wt)Hras(TG.AC/wt), p53(Val135/wt)Hras(wt/wt), and p53(Val135/wt)Hras(TG.AC/wt) mice were principally squamous cell carcinomas with varying degree of invasiveness. Particularly, tumors in p53(Val135/wt)Hras(TG.AC/wt) mice exhibited the most rapid growth and the extreme form of tumor invasion. Microarray analysis revealed that dominant-negative p53 (Val135) and activated H-ras affected several cellular processes involved in tumorigenesis possibly through its effects on apoptosis, cell cycle arrest, and Ras-mitogen-activated protein kinase pathways. The present study provides the first in vivo evidence that a germ line p53 mutation and activated H-ras act synergistically to profoundly enhance tumor progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254190     DOI: 10.1158/1541-7786.MCR-05-0144

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  3 in total

1.  Driven to death: Inhibition of farnesylation increases Ras activity and promotes growth arrest and cell death [corrected].

Authors:  Mandy Geryk-Hall; Yanwen Yang; Dennis P M Hughes
Journal:  Mol Cancer Ther       Date:  2010-04-20       Impact factor: 6.261

2.  Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme.

Authors:  Józefa Węsierska-Gądek; Eva Walzi; Iva Dolečkova; Gerald Schmid
Journal:  Cancer Microenviron       Date:  2009-09-04

3.  Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas.

Authors:  Manuel António Campos; Sofia Macedo; Margarida Sá Fernandes; Ana Pestana; Joana Pardal; Rui Batista; João Vinagre; Agostinho Sanches; Armando Baptista; José Manuel Lopes; Paula Soares
Journal:  Genes (Basel)       Date:  2020-07-06       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.